Search Videos and More

Showing 25 - 36 of 50 results

Previous| 1... 2 | 3 | 4 ...5 |Next


Blood Cancer Research: Clinical trial helps younger patient Video

Blood Cancer Research: Clinical trial helps younger patient

Dr. Matthew Davids presented a study that demonstrated the ibrutinib+FCR drug combination keeps chronic lymphocytic leukemia in young patients in remission for several years.
COVID-19 vaccine and blood cancer Video

COVID-19 vaccine and blood cancer

Dr. Nikhil Munshi and colleagues reported a study demonstrating that COVID-19 vaccination offers less protection for multiple myeloma patients, reinforcing the need for these patients to use additional precautions.
Blood Cancer: Higher rates of precursor in high-risk individuals Video

Blood Cancer: Higher rates of precursor in high-risk individuals

Dr. Irene Ghobrial and Dr. Habib El-Khoury shared the first results from the Promise study, which screens individuals at high risk for multiple myeloma.
Drug Combination Found to Keep Chronic Lymphocytic Leukemia in Young Patients in Remission for Several Years News

Drug Combination Found to Keep Chronic Lymphocytic Leukemia in Young Patients in Remission for Several Years

A new study by Dana-Farber Cancer Institute researchers suggests that a 2.5-year regimen involving ibrutinib and chemoimmunotherapy can provide deep, and lasting remissions for patients with chronic lymphocytic leukemia (CLL).
Molecular Analysis Advances Risk Profiling and Assessment of Immunotherapy Response in Smoldering Myeloma News

Molecular Analysis Advances Risk Profiling and Assessment of Immunotherapy Response in Smoldering Myeloma

Molecular and genetic research by scientists at Dana-Farber Cancer Institute has advanced the categorization of different risk groups in patients with smoldering myeloma, a premalignant condition that can – but doesn’t always – progress to the blood cancer, multiple myeloma.
American Society of Hematology (ASH) Annual Meeting News

American Society of Hematology (ASH) Annual Meeting

As leaders in blood and blood cancer research, physicians and scientists from Dana-Farber Cancer Institute shared advances and insights at the 63rd Annual Meeting of the American Society of Hematology (ASH) on December 11–14, 2021 in Atlanta, Georgia
New Study Reveals Elevated Rates of Blood Cancer Precursor Condition in Groups at High Risk for Multiple Myeloma News

New Study Reveals Elevated Rates of Blood Cancer Precursor Condition in Groups at High Risk for Multiple Myeloma

The first results from the largest screening study yet conducted in the United States of individuals at above-average risk for the blood cancer multiple myeloma have revealed higher rates of a myeloma precursor condition in older adults who are Black or who have a close family member with a current or past blood cancer.
ASH 2021 Featured Oral Presentations Document

ASH 2021 Featured Oral Presentations

The Annual Meeting of the American Society of Hematology (ASH) will take place December 11-14th. To keep-up with latest advances, the live schedule of oral presentations by Dana-Farber faculty is attached for your convenience.
Discovery May Lead to Expanded Donor Pool for Stem Cell Transplants for Patients with Cancer News

Discovery May Lead to Expanded Donor Pool for Stem Cell Transplants for Patients with Cancer

Researchers find that in many cases people with a condition known as clonal hematopoiesis can safely serve as stem cell transplant donors.
Finding New Targets for Acute Myeloid Leukemia in Children News

Finding New Targets for Acute Myeloid Leukemia in Children

Looking for genes AML needs for everyday survival turned up two strong ‘hits’ to pursue for therapeutic development.
Study Results Support Stem Cell Transplantation for Older Patients with Myelodysplastic Syndromes News

Study Results Support Stem Cell Transplantation for Older Patients with Myelodysplastic Syndromes

Although stem cell transplantation is the only current therapy with the potential to cure myelodysplastic syndromes (MDS), it is rarely used as an initial treatment for older patients because it hasn’t been proven superior to other therapies. New research by Dana-Farber Cancer Institute investigators stands to overturn that practice.
Mantle Cell Lymphoma Clinical Trial Document

Mantle Cell Lymphoma Clinical Trial

Targeted combination therapy for mantle cell lymphoma with minimal residual disease assessment.

Showing 25 - 36 of 50 results

Previous| 1... 2 | 3 | 4 ...5 |Next